Open AccessPD11 ‐ Omalizumab in children: experience in the Immunoallergology Department
Author(s) -
Aguiar Rita,
Silva Pedro,
Cabral Duarte Fátima,
Mendes Ana,
Célia Costa Ana,
Pereira Manuel Barbosa
Publication year - 2014
Publication title -
clinical and translational allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.979
H-Index - 37
ISSN - 2045-7022
DOI - 10.1186/2045-7022-4-s1-p11
Subject(s) - omalizumab , medicine , azathioprine , asthma , discontinuation , adverse effect , atopic dermatitis , allergy , immunoglobulin e , population , pediatrics , dermatology , immunology , antibody , disease , environmental health
Omalizumab is a monoclonal antibody approved for the treatment of severe allergic asthma for patineis above 6 years old in Europe, but its use has been described successfully in other IgE-mediated diseases.